The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy.

MLA

Miyake, Kentaro, et al. “The Combination of Temozolomide-Irinotecan Regresses a Doxorubicin-Resistant Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model of Recurrent Ewing’s Sarcoma with a FUS-ERG Fusion and CDKN2A Deletion: Direction for Third-Line Patient Therapy.” Oncotarget, vol. 8, no. 61, Sept. 2017, pp. 103129–36. EBSCOhost, https://doi.org/10.18632/oncotarget.20789.

APA

Miyake, K., Murakami, T., Kiyuna, T., Igarashi, K., Kawaguchi, K., Miyake, M., Li, Y., Nelson, S. D., Dry, S. M., Bouvet, M., Elliott, I. A., Russell, T. A., Singh, A. S., Eckardt, M. A., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Endo, I., … Hoffman, R. M. (2017). The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy. Oncotarget, 8(61), 103129–103136. https://doi.org/10.18632/oncotarget.20789

Chicago

Miyake, Kentaro, Takashi Murakami, Tasuku Kiyuna, Kentaro Igarashi, Kei Kawaguchi, Masuyo Miyake, Yunfeng Li, et al. 2017. “The Combination of Temozolomide-Irinotecan Regresses a Doxorubicin-Resistant Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model of Recurrent Ewing’s Sarcoma with a FUS-ERG Fusion and CDKN2A Deletion: Direction for Third-Line Patient Therapy.” Oncotarget 8 (61): 103129–36. doi:10.18632/oncotarget.20789.